Vincristine/Irinotecan Upfront Window Treatment of High-risk Hepatoblastoma: A Report from the Children’s Oncology Group (COG) AHEP0731 Study Committee

PURPOSE: The identification of new therapies for high-risk (HR) hepatoblastoma (HB) is challenging. Children’s Oncology Group Study AHEP0731 included a HR stratum to explore the efficacy of novel agents. We report the response rate to vincristine/irinotecan and the outcome of high-risk HB patients....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Katzenstein, HM, Furman, WL, Malogolowkin, MH, Krailo, MD, McCarville, MB, Towbin, AJ, Tiao, GM, Finegold, M, Ranganathan, S, Dunn, SP, Langham, MR, McGahren, ED, Rodriguez-Galindo, C, Meyers, RL
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5665173/
https://ncbi.nlm.nih.gov/pubmed/28211941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30591
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados